DUBLIN--(BUSINESS WIRE)--The "Global Monoclonal Antibody Partnering Terms and Agreements 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
The Global Monoclonal antibody Partnering Terms and Agreements 2012 to 2018: Deal trends, players, financials and forecasts report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:
- Monoclonal antibodies
- Murine mAb
- Chimeric mAb
- Humanized mAb
- Human aAb
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2012, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.
Report scope
Global Monoclonal antibody Partnering Terms and Agreements 2012 to 2018 includes:
- Trends in monoclonal antibodies dealmaking in the biopharma industry since 2012
- Analysis of monoclonal antibodies deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 700 monoclonal antibodies deal records
- The leading monoclonal antibodies deals by value since 2012
- Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2012
Deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
-
Monoclonal antibodies type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in monoclonal antibody dealmaking
Chapter 3 - Leading monoclonal antibody deals
Chapter 4 - Most active monoclonal antibody dealmakers
Chapter 5 - Monoclonal antibody contracts dealmaking directory
Chapter 6 - Monoclonal antibody dealmaking by technology type
Chapter 7 - Partnering resource center
For more information about this report visit https://www.researchandmarkets.com/research/2tqsrc/global_monoclonal?w=4
